申请人:——
公开号:US20040010022A1
公开(公告)日:2004-01-15
The present invention relates to compounds of formula I:
1
wherein one of R
1
and R
4
is selected from the group consisting of H, and optionally substituted C
1-6
alkyl, C
3-7
cycloalkyl, C
3-7
cycloalkyl-C
1-4
alkyl, and phenyl-C
1-4
alkyl; and the other of R
1
and R
4
is an optionally substituted C
9-14
aryl group; R
2
and R
3
are either:
(i) independently selected from H, R, R′, SO
2
R, C(═O)R, (CH
2
)
n
NR
5
R
6
, where n is from 1 to 4 and R
5
and R
6
are independently selected from H and R, where R is optionally substituted C
1-4
alkyl, and R′ is optionally substituted phenyl-C
1-4
alkyl, or
(ii) together with the nitrogen atom to which they are attached, form an optionally substituted C
5-7
heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT
2B
receptor.
本发明涉及公式I的化合物:
1
其中R
1
和R
4
之一选自由H、以及可选地取代的C
1-6
烷基、C
3-7
环烷基、C
3-7
环烷基-C
1-4
烷基和苯基-C
1-4
烷基组成的组;R
1
和R
4
的另一个是可选地取代的C
9-14
芳基基团;R
2
和R
3
是:
(i)独立地选自H、R、R′、SO
2
R、C(═O)R、(CH
2
)
n
NR
5
R
6
,其中n是从1到4,R
5
和R
6
独立地选自H和R,其中R是可选地取代的C
1-4
烷基,R′是可选地取代的苯基-C
1-4
烷基,或
(ii)与它们连接的氮原子一起,形成一个可选地取代的C
5-7
杂环基团;以及它们作为药物的使用,特别用于治疗通过5-HT
2B
受体的拮抗作用减轻的状况。